Bardoxolone Methyl – Phase 2 Study Yields Positive Results
In a 52-week study, patients taking bardoxolone methyl
experienced sustained, significant increases in estimated
glomerular filtration rate, a key measure of kidney function.
Bardoxolone methyl is a novel anti-inflammatory,
anti-oxidative-stress compound.
Reata has entered into a global collaboration with Abbott to
jointly develop and commercialize new antioxidant inflammation
modulators (AIMs) in a broad range of therapeutic areas.
Reata Pharmaceuticals, Inc. is a private company aiming to build
an enduring, fully integrated pharmaceutical company delivering new
and novel medicines for deadly and difficult-to-treat diseases.
